Home » COVID-19, Headlines, Health » Nigerian scientists say drug for river blindness, can cure COVID-19

Nigerian scientists say drug for river blindness, can cure COVID-19

By Abankula

Vice President Yemi Osinbajo has welcomed efforts by a team of Nigerian scientists investigating the efficacy of Ivermectin drug in the treatment of COVID-19.

The team, which is composed of Nigerian scholars at home and abroad, has also submitted its report on the usefulness of the drug to the World Health Organisation.

The WHO has appointed a Peer Review expert from the United Kingdom.

Osinbajo expressed excitement that Nigeria and Nigerians “are at the cutting edge of scientific research into the COVID-19 treatment.”

According to him, “we have an opportunity here and I am so fascinated to hear this drug has been used in the treatment of River Blindness in this country.”

While commending the efforts of the team, Prof. Osinbajo added that with the report, Nigeria is at an advantage both in knowledge and availability of the drug, especially since Ivermectin has been found useful not only in the treatment of COVID-19, but also as a prophylactic medication.

He disclosed that the Federal Government will explore further ways to support the research for the benefit of Nigerians and humanity generally, while also advancing the effective funding of scientific research in the country.

The VP spoke after he was briefed virtually on the report by a team of scientists led by Prof. Femi Babalola, the Principal investigator, and Prof. Chris Bode, the Chief Medical Director of LUTH.

Members of the group named IVERCOVID Research Group, apart from Babalola and Bode are the Chairman of the Medical Advisory Council at LUTH, Prof. Lanre Adeyemo; a US-based Clinical Pharmacologist, Prof. Adesuyi Ajayi.

Others are virologists Prof. S.A Omilabu and Dr. Olumuyiwa Salu; and also the Project Coordinator, Dr. Felix Alakaloko.

Both Prof. Babalola and the CMD, LUTH commended the Buhari Presidency for encouraging the research and thanked the Vice President for his personal role and support.

The report is titled, “A randomised controlled trial for the repurposing of Ivermectin in the management of COVID-19,” and highlights are discussed below:

The research, carried out in the Lagos University Teaching Hospital (LUTH) was undertaken following the report of a 5,000-fold reduction in viral load by Australian workers with in-vitro use of Ivermectin on COVID-19 in culture.

The PI has worked extensively with Ivermectin on the Onchocerciasis-River Blindness control programme, through which many Nigerians have used Ivermectin.

FINDINGS

The study revealed that the mechanism of action of Ivermectin, include “Inhibiting viral entry into cells nucleus; and “Direct suppression of viral RNA load of SARS CoV 2,” among others.

Ivermectin is orally absorbed with higher absorption as a solution better than tablets, and “The Mean Residence Time” (MRT) is 3.4 days. This informs the suggested frequency of dosing, i.e. twice a week.

The research’s Null hypothesis noted that: “Safe doses of Ivermectin are not useful in the treatment of patients with virology proven COVD-19 disease, does not lower viral load, and does not shorten time to negativity, neither does it cause improvement in clinical parameters when compared to Lopinavir/Ritonavir/Placebo.”

But its Alternative Hypothesis revealed that, “Safe doses of Ivermectin are useful in the treatment of patients with virology proven COVID-19 disease, lowering viral load, shortening time to negativity, and causing improvement in clinical parameters when compared with Lopinavir/Ritonavir/Placebo.”

In its results so far, the Study noted that the randomisation was effective based on distribution of age, sex and some clinical presentation at baseline such as cough and fever.

The overall results showed that the “Days-To-Negative (DTN) reduced by 3.8 days overall. While a few patients are negative by day two, 50 per cent are negative by day 5.”

The study indicated that Clinical trials of Ivermectin have been carried out in at least 21 countries worldwide, including Nigeria. It referenced the “Meta-analysis of clinical trials of Ivermectin to treat COVID-19 infection” by Dr. Andrew Hill, Department of Pharmacology, University of Liverpool, UK.

Highlighting the practical applications, the Study proposed that “Ivermectin should be considered for adoption into the uniform treatment guidelines of COVID- 19 in Nigeria,” noting the “potential use of ivermectin as prophylaxis Pending the rollout of vaccination programs or alongside it.”

However, the Study emphasized that Ivermectin “is not meant to replace other COVID-19 measures such as social distancing, face masking and hygiene, or vaccinations,” adding that, “It is possibly an additional tool which can be deployed to fight the pandemic.”

The group stated that it has forwarded a report of its findings to NAFDAC.

-PM News

Short URL: http://newnigerianpolitics.com/?p=59034

Posted by on Jan 12 2021. Filed under COVID-19, Headlines, Health. You can follow any responses to this entry through the RSS 2.0. You can leave a response or trackback to this entry

Leave a Reply

Trump exit: I’m not interested in applying for fresh Green Card soon – Soyinka

Headlines

Sowore not leaving Kuje Prison quickly, court grants harsh bail conditions

Categories

With new Ohaneze leadership, Igbos ready to play politics beyond the Niger

Browse Africa & World Politics

Featuring Top 3/2056 of Africa & World Politics

Browse National Politics

Featuring Top 5/1060 of National Politics

Dangote broke my heart in 1000 pieces: Atlanta babe Bea Lewis

Browse NNP Columnists

Featuring Top 10/1442 of NNP Columnists

Pictures: Houston Based Nigerian doctor, Ben Okigbo, kills nurse wife and tried to strangle his 2 sons before hanging himself

Advertisements

--

FEATURED VIDEOS

2023 presidency: Ex-senators, others storm Alaafin, Olubadan’s palaces for Tinubu

ARCHIVES

January 2021
S M T W T F S
« Dec    
 12
3456789
10111213141516
17181920212223
24252627282930
31  

© 2021 New Nigerian Politics. All Rights Reserved. Log in - Designed by Gabfire Themes